These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30769245)

  • 1. Rapid assessment of enhanced safety surveillance for influenza vaccine.
    Alguacil-Ramos AM; Portero-Alonso A; Pastor-Villalba E; Muelas-Tirado J; Díez-Domingo J; Sanchis-Ferrer A; Lluch-Rodrigo JA
    Public Health; 2019 Mar; 168():137-141. PubMed ID: 30769245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Dos Santos G; Nguyen BY; Damaso S; Godderis L; Martínez-Gómez X; Eckermann T; Loos H; Salamanca de la Cueva I; Shende V; Schmidt AC; Yeakey A
    Drug Saf; 2020 Mar; 43(3):265-279. PubMed ID: 31884676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009-2010 and 2010-2011. Valencian community, Spain].
    Alguacil Ramos AM; Lluch Rodrigo JA; Portero Alonso A; Martín Ivorra R; Pastor Villalba E
    Rev Esp Salud Publica; 2012; 86(3):241-51. PubMed ID: 22991081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis.
    Dos Santos G; Shende V; Damaso S; Yeakey A
    Adv Ther; 2019 Dec; 36(12):3340-3355. PubMed ID: 31595482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia.
    Clothier HJ; Crawford N; Russell MA; Buttery JP
    Euro Surveill; 2017 May; 22(20):. PubMed ID: 28552101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England.
    de Lusignan S; Dos Santos G; Correa A; Haguinet F; Yonova I; Lair F; Byford R; Ferreira F; Stuttard K; Chan T
    BMJ Open; 2017 May; 7(5):e015469. PubMed ID: 28515198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season.
    Spila Alegiani S; Alfonsi V; Appelgren EC; Ferrara L; Gallo T; Alicino C; Pascucci MG; Aquilani S; Spadea A; Tafuri S; Rizzo C
    BMC Public Health; 2018 Dec; 18(1):1401. PubMed ID: 30577729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons.
    Li R; Stewart B; McNeil MM; Duffy J; Nelson J; Kawai AT; Baxter R; Belongia EA; Weintraub E
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):928-34. PubMed ID: 27037540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.
    Bricout H; Chabanon AL; Souverain A; Sadorge C; Vesikari T; Caroe TD
    Euro Surveill; 2017 May; 22(18):. PubMed ID: 28494843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Moro PL; Cano M; Jankosky C
    Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system.
    Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA
    Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.
    de Lusignan S; Dos Santos G; Byford R; Schuind A; Damaso S; Shende V; McGee C; Yonova I; Ferreira F
    Adv Ther; 2018 Aug; 35(8):1199-1214. PubMed ID: 29995300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
    Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine.
    Demeulemeester M; Lavis N; Balthazar Y; Lechien P; Heijmans S
    Hum Vaccin Immunother; 2017 Apr; 13(4):889-894. PubMed ID: 27960593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.
    Alicino C; Merlano C; Zappettini S; Schiaffino S; Della Luna G; Accardo C; Gasparini R; Durando P; Icardi G
    Hum Vaccin Immunother; 2015; 11(1):91-4. PubMed ID: 25483520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study.
    Stuurman AL; Verstraeten T; De Schryver A
    Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.